Session I: Quality Control and Characterization ❱
Data requirements for iPS cells that are accepted by repositories for distribution, identifying a set of characterization assays that should be performed, how best to deal with documenting genomic stability and pluripotency, and repository logistics (sample handling, storage and distribution).
"The Central Role of Biorepositories in the iPSC Field"
Michael Sheldon, RUCDR Infinite Biologics
"Genetic stability of human pluripotent stem cells"
Peter Andrews, International Stem Cell Initiative (ISCI)/Sheffield
"Procurement, banking, testing and supply of hPSCs for both research and clinical application: experiences of the UK Stem Cell Bank and a consensus from the International Stem Cell Banking Initiative"
Glyn Stacey, National Institute for Biological Standards and Control (NIBSC)
"The European Bank for induced pluripotent Stem Cells approach to cell line characterization"
Tim Allsopp, European Bank for induced pluripotent Stem Cells (EBISC)/Pfizer
"Standardized Reagents to Support iPS Cell Generation, Validation, and Banking"
Erik Hadley, Stem Cell Technologies